Acetyl hexapeptide-8
acetyl hexapeptide-3 (former INCI name), Ac-EEMQRR-NH2, acetyl glutamyl-glutamyl-methionyl-glutaminyl-arginyl-arginine amide
Acetyl hexapeptide-8 is a six-amino-acid mimic of the N-terminus of SNAP-25, marketed as a topical alternative to botulinum toxin. The receptor-level rationale is coherent and the peptide does inhibit neurotransmitter release in cell systems. Whether a topically applied cream delivers enough intact peptide to a neuromuscular junction to matter is unproven, and the best available penetration data, produced by FDA scientists, suggest it does not.
Mechanism
Neurotransmitter release at the neuromuscular junction requires assembly of the SNARE complex, a four-helix bundle formed from synaptobrevin (VAMP) on the vesicle membrane and syntaxin-1 plus SNAP-25 on the plasma membrane. This complex zippers the vesicle to the membrane and drives calcium-dependent fusion, releasing acetylcholine. Botulinum neurotoxin type A works by proteolytically cleaving SNAP-25, destroying the complex and paralysing the muscle.
Acetyl hexapeptide-8 reproduces the first six residues of SNAP-25 as a free, acetylated and C-terminally amidated hexapeptide. The design hypothesis is competitive interference: the free hexapeptide occupies SNAP-25's position in the assembling complex, destabilises it, and reduces the efficiency of vesicle fusion without cleaving anything. Blanes-Mira and colleagues demonstrated this in 2002 in cell-based systems. The peptide inhibited calcium-dependent exocytosis by interfering with the formation or stability of the SNARE complex. A detail usually reported the wrong way round: the 2002 paper found the hexapeptide inhibited neurotransmitter release with a potency similar to botulinum toxin A but with much lower efficacy. Potency and efficacy are not the same thing, and it is the efficacy gap, not a potency gap, that separates the two.
The unresolved problem is delivery. A neuromuscular junction sits beneath the epidermis, beneath the dermis, at the level of the facial mimetic muscle. A hydrophilic, charged hexapeptide has no obvious route there. A 2025 review in the International Journal of Molecular Sciences summarises the position: because of its hydrophilic nature and relatively large molecular size, the peptide faces limited permeability through the lipophilic stratum corneum, effective dermal delivery is challenging, its ability to reach neuromuscular junctions remains uncertain, and the biological mechanisms behind the reported cosmetic effects (particularly any inhibition of muscle contraction after topical application) remain incompletely understood.
What the research shows
Blanes-Mira and colleagues (2002) is the founding paper. It combined mechanistic work (showing the hexapeptide interferes with SNARE complex formation and inhibits calcium-dependent exocytosis) with an in vivo arm in which a 10% oil-in-water emulsion reduced wrinkle depth by up to 30% over 30 days in healthy women volunteers. The topographic arm is thinly reported by modern standards and the authors were connected to the developer.
Wang and colleagues (2013) ran a randomised, placebo-controlled study in 60 Chinese subjects, allocated 3:1 to peptide or placebo, applied twice daily to periorbital wrinkles for four weeks. On subjective global assessment the anti-wrinkle efficacy rate was 48.9% versus 0% for placebo; on objective silicone-replica analysis, roughness parameters all decreased in the peptide group (p < 0.01) with no obvious decrease in placebo. This is the most rigorously reported efficacy trial of the ingredient. The paper does not state the peptide concentration used, and the frequently repeated claim that it tested a 10% cream is not supported by the published report; neither is any statement about who funded it, so it should not be asserted either way. Four weeks remains a very short window for an anti-ageing endpoint.
Raikou and colleagues (2017) ran a four-arm randomised study in 24 volunteers (six per arm) over 60 days, comparing acetyl hexapeptide-3 alone, tripeptide-10 citrulline alone, the combination, and neither. They concluded that the results confirm the anti-wrinkle activity of acetyl hexapeptide-3 and that it significantly decreased transepidermal water loss. With six subjects per arm and a large number of pairwise between-group comparisons, this is hypothesis-generating at best. Palmieri and colleagues (2020) is weaker still and is often misdescribed: the authors themselves call it a spontaneous, anecdotal, retrospective study of 26 patients applying a 10% acetyl hexapeptide-8 gel-cream to scars and skin lesions, with no control group. It reported improved hydration, elasticity and sebum values and improved patient self-image. It is framed by its own authors as temporary cosmetic camouflage, and it establishes nothing about efficacy.
The penetration literature is where the story gets awkward, and it is the strongest evidence in this monograph. Kraeling and colleagues (2015), working at the FDA's Center for Food Safety and Applied Nutrition, applied a 10% oil-in-water emulsion at 2 mg per square centimetre to excised human cadaver and hairless guinea pig skin in diffusion cells. After 24 hours the majority of the dose was washed off the surface. Of what penetrated, 0.22% of the applied dose remained in human stratum corneum and 0.01% in the epidermis; no peptide at all was detected in the dermis or in the buffer beneath the skin. Hoppel and colleagues (2015) showed on porcine ear skin that a multiple water-in-oil-in-water emulsion significantly increases penetration relative to simple oil-in-water and water-in-oil vehicles, which is, in effect, an admission that passive delivery from ordinary vehicles does not work well.
An honest summary: acetyl hexapeptide-8 probably produces a small measurable improvement in wrinkle appearance in short trials. No published in vivo study has demonstrated that it does so by relaxing muscle, the claimed effect sizes vary widely with the measurement technique, and the comparison to botulinum toxin (which produces unambiguous, clinically obvious paralysis) is not supported by anything in the literature.
Evidence assessment
Mixed evidence
Several small randomised placebo-controlled human trials report wrinkle or roughness improvements, but they are short, use inconsistent quantification methods, and no in vivo study has demonstrated the muscle-relaxant mechanism the product is sold on.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
A synthetic hexapeptide (Argireline) with antiwrinkle activity Mixed evidence
The hexapeptide inhibited neurotransmitter release by interfering with formation or stability of the SNARE complex, with potency similar to botulinum toxin A but much lower efficacy; the 10% emulsion reduced wrinkle depth by up to 30% over 30 days. No oral toxicity or primary irritation was seen at high doses.
The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study Mixed evidence
Subjective anti-wrinkle efficacy was 48.9% in the peptide group versus 0% in placebo; objective roughness parameters all decreased in the peptide group (p<0.01) with no obvious decrease in placebo.
In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation Preclinical only
Most of the applied dose was washed from the skin surface. Of the peptide that penetrated, 0.22% of the applied dose was recovered from human stratum corneum and 0.01% from the epidermis; no peptide was detected in the dermis or in the buffer beneath the skin.
Topical delivery of acetyl hexapeptide-8 from different emulsions: influence of emulsion composition and internal structure Preclinical only
A multiple water-in-oil-in-water emulsion significantly increased penetration into porcine skin compared with simple oil-in-water and water-in-oil emulsions, with water-rich vehicles clearly superior to the oil-rich vehicle.
Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy Mixed evidence
Concludes that the peptide's hydrophilic nature and molecular size limit permeability through the stratum corneum, that effective dermal delivery is challenging, that its ability to reach neuromuscular junctions remains uncertain, and that the mechanisms behind reported cosmetic effects (particularly any inhibition of muscle contraction after topical application) remain incompletely understood.
The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study Limited evidence
Reported significant between-group differences on microtopography parameters and transepidermal water loss at various timepoints; the authors concluded that the results confirm the anti-wrinkle activity of acetyl hexapeptide-3 and that it significantly decreased transepidermal water loss.
Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8 Limited evidence
Investigators reported improvement in hydration, elasticity and sebum measures and in patients' self-image, with no allergic reactions documented.
Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet Limited evidence
Corneometer, tewameter and cutometer results were all non-significant (p>0.05). On the Crow's Feet Grading Scale the acetylhexapeptide-3 arm fell 0.86 points static and 0.57 dynamic, against 0.86 and 1.0 in the placebo arm. Local complaints (itching, stinging, burning, dryness) were reported in both the peptide and placebo arms.
Safety
The topical safety record is reassuring as far as it goes. The 2002 founding paper reported no oral toxicity in vivo and no primary irritation at high doses. Reported reactions in trials are local and mild (transient itching, stinging or burning), and in the 2023 crow's feet trial these occurred in the placebo arm at a similar or higher rate than in the peptide arms, pointing at the vehicle rather than the peptide. The meaningful limits of this record are that it covers topical exposure only, that the trials are short (four weeks to 60 days), that long-term repeated-use data are absent, and that nothing whatsoever supports injection. There is a logical link between the reassuring safety record and the doubtful efficacy: if the peptide genuinely did reach neuromuscular junctions in quantity, the safety question would become a different and more serious one. The good safety record and the poor penetration are two views of the same fact.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | Permitted as a cosmetic ingredient under the UK Cosmetics Regulation (retained EC No 1223/2009), with no Annex restriction. Anti-wrinkle claims must be substantiated under the Cosmetic Products Enforcement Regulations 2013, and comparative claims against a licensed medicine such as botulinum toxin would attract regulatory attention. Not licensed by the MHRA as a medicine. |
| United States | A cosmetic ingredient, not an approved drug. It requires no FDA pre-market approval and has none. Marketing it as a substitute for botulinum toxin, or making claims about muscle relaxation, pushes a product into unapproved-drug territory. No prescription or over-the-counter product containing it is FDA-approved. |
| WADA (sport) | Not listed on the WADA Prohibited List and not a monitored substance. |
Questions
No. The rationale is borrowed from botulinum toxin (both act on SNAP-25), but botulinum toxin is a catalytic protease injected directly into muscle, while acetyl hexapeptide-8 is a non-catalytic competitor applied to the skin surface. No published in vivo study has shown it inhibits muscle contraction in a person, and the 2025 review of this literature states that its ability to reach neuromuscular junctions remains uncertain. The comparison is a marketing device, not a pharmacological equivalence.
Barely. In the best-controlled in vitro study, run by FDA scientists on excised human skin, 0.22% of the applied dose was found in the stratum corneum, 0.01% in the epidermis, and none at all in the dermis or the fluid beneath it after 24 hours. Most of the dose simply washed off the surface. That is a serious problem for a mechanism that requires the peptide to reach a nerve terminal at muscle depth.
Nothing chemically. They are the same molecule. Acetyl hexapeptide-3 was the earlier INCI name and was reclassified to acetyl hexapeptide-8. Older papers use -3, newer labels use -8, and both refer to Ac-EEMQRR-NH2.
Probably a small something. Several short trials report measurable reductions in wrinkle depth or roughness versus placebo, and the best of them (n=60, four weeks) found objective roughness parameters falling significantly. But the trials are short, effect sizes vary widely with the measurement method, several supporting studies have six or seven subjects per arm, and nothing published demonstrates the muscle-relaxant mechanism the product is sold on.